TABLE 1. Estimated vaccination coverage with selected vaccines and doses among adolescents aged 13–17 years,* by age at interview — National Immunization Survey–Teen, United States, 2022.
| Vaccine/Population group | Age at 2022 interview, yrs, % (95% CI)† |
Total, % (95% CI)† |
|||||
|---|---|---|---|---|---|---|---|
| 13 (n = 3,198) |
14 (n = 3,399) |
15 (n = 3,219) |
16 (n = 3,208) |
17 (n = 3,019) |
2022 (N = 16,043) |
2021 (N = 18,002) |
|
|
Tdap ≥1 dose§
|
85.1 (81.7–88.0) |
90.7 (88.8–92.3)¶ |
91.5 (89.6–93.1)¶ |
91.1 (88.9–93.0)¶ |
91.4 (89.2–93.2)¶ |
89.9 (88.9–90.9)
|
89.6 (88.6–90.5)
|
|
MenACWY**
| |||||||
| ≥1 dose |
84.5 (81.3–87.2) |
89.2 (87.1–91.0)¶ |
89.0 (86.7–91.0)¶ |
89.8 (87.4–91.8)¶ |
90.7 (88.7–92.3)¶ |
88.6 (87.6–89.6)
|
89.0 (87.9–90.0)
|
| ≥2 doses†† |
NA |
NA |
NA |
NA |
60.8 (57.5–63.9) |
60.8 (57.5–63.9)
|
60.0 (56.6–63.3)
|
|
MenB§§
| |||||||
| ≥1 dose |
NA |
NA |
NA |
NA |
29.4 (26.5–32.4)¶ |
29.4 (26.5–32.4)
|
31.4 (28.2–34.8)
|
| ≥2 doses |
NA |
NA |
NA |
NA |
11.9 (10.0–14.1) |
11.9 (10.0–14.1)
|
NA
|
|
HPV¶¶ vaccine
| |||||||
|
All adolescents
| |||||||
| ≥1 dose |
68.9 (65.4–72.2) |
75.8 (73.0–78.4)¶ |
78.5 (75.7–81.1)¶ |
79.6 (76.8–82.2)¶ |
77.4 (74.5–80.0)¶ |
76.0 (74.7–77.3)
|
76.9 (75.6–78.2)
|
| HPV vaccine UTD*** |
50.0 (46.4–53.5) |
60.3 (57.1–63.4)¶ |
65.8 (62.7–68.8)¶ |
68.8 (65.8–71.7)¶ |
68.3 (65.3–71.2)¶ |
62.6 (61.1–64.0)
|
61.7 (60.2–63.2)
|
|
Females
| |||||||
| ≥1 dose |
72.8 (67.7–77.3) |
76.5 (72.4–80.2) |
79.5 (75.3–83.2)¶ |
81.3 (76.8–85.1)¶ |
79.0 (75.0–82.5)¶ |
77.8 (75.8–79.6)
|
78.5 (76.6–80.4)
|
| HPV UTD |
52.3 (47.1–57.4) |
61.7 (57.3–65.9)¶ |
68.5 (63.9–72.8)¶ |
70.8 (66.2–75.0)¶ |
70.9 (66.7–74.8)¶ |
64.6 (62.5–66.6)
|
63.8 (61.5–65.9)
|
|
Males
| |||||||
| ≥1 dose |
65.0 (60.0–69.7) |
75.1 (71.2–78.7)¶ |
77.5 (73.7–80.9)¶ |
78.1 (74.3–81.4)¶ |
75.9 (71.8–79.5)¶ |
74.4 (72.5–76.1)
|
75.4 (73.5–77.2)
|
| HPV UTD |
47.6 (42.8–52.4) |
58.8 (54.3–63.2)¶ |
63.3 (59.0–67.4)¶ |
67.0 (62.9–70.8)¶ |
66.0 (61.7–70.0)¶ |
60.6 (58.6–62.6)
|
59.8 (57.6–61.8)
|
|
MMR ≥2 doses
|
90.5 (87.6–92.8) |
92.6 (90.4–94.4) |
91.0 (88.7–92.8) |
92.0 (90.0–93.6) |
89.9 (87.3–92.0) |
91.2 (90.2–92.1)
|
92.2 (91.2–93.2)
|
|
Hepatitis A vaccine ≥2 doses†††
|
84.8 (81.5–87.5) |
86.6 (83.9–88.9) |
86.7 (84.2–88.8) |
84.6 (81.9–87.0) |
82.3 (79.7–84.7) |
85.0 (83.8–86.1)
|
85.0 (83.8–86.1)
|
|
Hepatitis B vaccine ≥3 doses
|
90.5 (87.6–92.8) |
92.6 (90.6–94.2) |
91.0 (88.8–92.8) |
91.2 (88.9–93.1) |
90.7 (88.3–92.6) |
91.2 (90.2–92.1)
|
92.3 (91.3–93.1)
|
|
Varicella
| |||||||
| History of varicella§§§ |
4.6 (3.4–6.3) |
6.4 (5.0–8.1) |
7.4 (5.8–9.3)¶ |
7.4 (5.9–9.2)¶ |
9.3 (7.5–11.4)¶ |
7.0 (6.3–7.8)
|
7.3 (6.5–8.2)
|
| No history of varicella disease | |||||||
| ≥1 dose vaccine |
93.5 (90.9–95.5) |
95.2 (93.5–96.5) |
93.4 (91.1–95.1) |
94.4 (92.8–95.6) |
93.8 (91.4–95.5) |
94.1 (93.2–94.8)
|
94.9 (94.0–95.7)
|
| ≥2 doses vaccine |
89.4 (86.2–91.9) |
91.9 (89.5–93.8) |
91.3 (89.1–93.2) |
91.1 (89.0–92.9) |
90.4 (87.9–92.4) |
90.8 (89.8–91.8)
|
91.5 (90.5–92.5)
|
| History of varicella or receipt of ≥2 varicella vaccine doses |
89.9 (86.9–92.3) | 92.4 (90.1–94.2) | 92.0 (89.9–93.7) | 91.8 (89.8–93.4) | 91.3 (89.0–93.1) | 91.5 (90.5–92.4) | 92.2 (91.2–93.1) |
Abbreviations: HPV = human papillomavirus; MenACWY = quadrivalent meningococcal conjugate vaccine; MenB = serogroup B meningococcal vaccine; MMR = measles, mumps, and rubella vaccine; NA = not applicable; NIS = National Immunization Survey; Tdap = tetanus, diphtheria, and acellular pertussis vaccine; UTD = up to date.
* Adolescents in the 2022 NIS–Teen were born during January 7, 2004–January 10, 2010.
† Estimates with 95% CIs widths >20 might not be reliable.
§ Includes percentages receiving Tdap vaccine at age ≥10 years.
¶ Statistically significant difference (p<0.05) in estimated vaccination coverage by age; referent group was adolescents aged 13 years.
** Includes percentages receiving MenACWY or an unknown type of meningococcal vaccine.
†† ≥2 doses of MenACWY or unknown type of meningococcal vaccine among adolescents aged 17 years at interview and does not include adolescents who received 1 dose of MenACWY vaccine at age ≥16 years.
§§ Calculated only among adolescents who were aged 17 years at time of interview with vaccine administered based on individual clinical decision.
¶¶ HPV vaccine, nine-valent (9vHPV), quadrivalent (4vHPV), or bivalent (2vHPV). For ≥1 dose and HPV UTD measures, percentages are reported among females and males combined (16,043) and for females only (7,623) and males only (8,420).
*** HPV vaccine UTD includes those with ≥3 doses, and those with 2 doses when the first HPV vaccine dose was initiated at age <15 years and there were ≥5 months minus 4 days between the first and second dose (https://www.cdc.gov/vaccines/programs/iis/cdsi.html). This update to the HPV recommendation occurred in December 2016.
††† In July 2020, ACIP revised recommendations for Hepatitis A vaccination to include catch-up vaccination for persons aged 2–18 years who have not previously received Hepatitis A vaccine at any age. https://pubmed.ncbi.nlm.nih.gov/32614811/
§§§ By parent or guardian report or provider records.